04.Issue 03 march 24 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 11, Issue : 03, March – 2024

Title:

A REVIEW ARTICLE ON PSORIASIS VULGARIS

Authors :

S. Shaheena Begum, PG. Pujitha Yadav

Abstract :

Psoriasis is a complex chronic inflammatory skin disease caused by the dynamic interplay between multiple genetic risk foci, environmental risk factors, and excessive immunological abnormalities. Psoriasis affects approximately 2% of the population worldwide, and dramatic advances have been achieved in the understanding and treatment options for psoriasis. Recent progress in biological therapies has revealed the fundamental roles of tumor necrosis factor-α, interleukin (IL)-23p19, and the IL-17A axis together with skin-resident immune cells and major signal transduction pathways in the pathogenesis of psoriasis.
In addition to IL-17-producing T helper17 cells, innate lymphoid cell (ILC)3 induces psoriasis rashes directly without T-cell/antigen interaction in response to the released antimicrobial peptides from activated keratinocytes and inflammatory cytokines.

Cite This Article:

Please cite this article in press S. Shaheena Begum et al., A Review Article On Psoriasis Vulgaris,, Indo Am. J. P. Sci, 2024; 11 (03).

Number of Downloads : 10

References:

1. Christophers E. Psoriasis—Epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001;26:314–320. doi: 10.1046/j.1365-2230.2001.00832.x. [PubMed] [CrossRef] [Google Scholar]
2. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013;133:377–385. doi: 10.1038/jid.2012.339. [PubMed] [CrossRef] [Google Scholar]
3. Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int. J. Dermatol. 1996;35:633–639. doi: 10.1111/j.1365-4362.1996.tb03687.x. [PubMed] [CrossRef] [Google Scholar]
4. Rachakonda T.D., Schupp C.W., Armstrong A.W. Psoriasis prevalence among adults in the united states. J. Am. Acad. Dermatol. 2014;70:512–516. doi: 10.1016/j.jaad.2013.11.013. [PubMed] [CrossRef] [Google Scholar]
5. Danielsen K., Olsen A.O., Wilsgaard T., Furberg A.S. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br. J. Dermatol. 2013;168:1303–1310. doi: 10.1111/bjd.12230. [PubMed] [CrossRef] [Google Scholar]
6. Ortonne J., Chimenti S., Luger T., Puig L., Reid F., Trueb R.M. Scalp psoriasis: European consensus on grading and treatment algorithm. J. Eur. Acad. Dermatol. Venereol. 2009;23:1435– 1444. doi: 10.1111/j.1468-3083.2009.03372.x. [PubMed] [CrossRef] [Google Scholar]
7. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595. [PubMed] [CrossRef] [Google Scholar]
8. Ko H.C., Jwa S.W., Song M., Kim M.B., Kwon K.S. Clinical course of guttate psoriasis:
Longterm follow-up study. J. Dermatol. 2010;37:894–899. doi: 10.1111/j.1346-
8138.2010.00871.x. [PubMed] [CrossRef] [Google Scholar]
9. Martin B.A., Chalmers R.J., Telfer N.R. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch. Dermatol. 1996;132:717–718. doi: 10.1001/archderm.1996.03890300147032. [PubMed] [CrossRef] [Google Scholar]
10. Navarini A.A., Burden A.D., Capon F., Mrowietz U., Puig L., Koks S., Kingo K., Smith C., Barker J.N., Network E. European consensus statement on phenotypes of pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:1792–1799. doi: 10.1111/jdv.14386. [PubMed] [CrossRef] [Google Scholar]
11. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006;298:321–328. doi: 10.1007/s00403-006-0703-z. [PubMed] [CrossRef] [Google Scholar]
12. Gerdes S., Mrowietz U., Boehncke W.H. Comorbidity in psoriasis. Hautarzt. 2016;67:438–444. doi: 10.1007/s00105-016-3805-3. [PubMed] [CrossRef] [Google Scholar]
13. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., Kaufmann R., Vogl T.J., Boehncke W.H. Psoriasis: A possible risk factor for development of coronary artery
calcification. Br. J. Dermatol. 2007;156:271–276. doi: 10.1111/j.1365-
2133.2006.07562.x. [PubMed] [CrossRef] [Google Scholar]
14. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X., Troxel A.B. The risk of stroke in patients with psoriasis. J. Investig. Dermatol.
2009;129:2411–2418. doi: 10.1038/jid.2009.112. [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
15. Prodanovich S., Kirsner R.S., Kravetz J.D., Ma F., Martinez L., Federman D.G. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch. Dermatol. 2009;145:700–703. doi: 10.1001/archdermatol.2009.94. [PubMed] [CrossRef] [Google Scholar]
16. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741. doi: 10.1001/jama.296.14.1735. [PubMed] [CrossRef] [Google Scholar]
17. Ahlehoff O., Gislason G.H., Charlot M., Jorgensen C.H., Lindhardsen J., Olesen J.B., Abildstrom S.Z., Skov L., Torp-Pedersen C., Hansen P.R. Psoriasis is associated with clinically significant cardiovascular risk: A danish nationwide cohort study. J. Intern. Med. 2011;270:147–157. doi: 10.1111/j.1365-2796.2010.02310.x. [PubMed] [CrossRef] [Google Scholar]
Web link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471628/